The Overexpression of LncRNA MEG3 Inhibits Cell Viability and Invasion and Promotes Apoptosis in Ovarian Cancer by Sponging MiR-205-5p

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2020 Jun 9

PMID 32509057

Citations 19

Authors

Pingping Tao

Binlie Yang

Huiya Zhang

Liyan Sun

Yungen Wang

Weiping Zheng

Affiliations

Soon will be listed here.

Abstract

Purpose: Ovarian cancer is a common and fatal cancer in women. The long non-coding RNA (lncRNA) MEG3 was reported to affect the cellular processes of ovarian cancer, but the mechanisms remain unclear. Here, we aimed to explore the potential regulatory mechanism of MEG3 in ovarian cancer.

Materials And Methods: A reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was conducted to analyze the expression levels of MEG3 and miR-205-5p in tissues and cell lines. An MTT assay was utilized to determine the cell viability of ovarian cancer SKOV-3 and OVCAR-8 cells. A flow cytometry analysis was employed to disclose the ovarian cancer cell apoptosis. The migration and invasion of SKOV-3 and OVCAR-8 cells were examined using a Transwell assay. A bioinformatics analysis indicated miR-205-5p as a direct target of MEG3, and a luciferase reporter assay was conducted to validate the interaction between MEG3 and miR-205-5p.

Results: MEG3 was significantly down-regulated, while miR-205-5p was up-regulated in ovarian cancer tissues and cell lines. The overexpression of MEG3 and the knockdown of miR-205-5p inhibited cell viability, migration and invasion but promoted the apoptosis rate in ovarian cancer cells. MiR-205-5p was identified as a downstream gene of MEG3 and is negatively regulated by MEG3. The introduction of miR-205-5p reversed the up-regulation of MEG3-mediated suppression effects on cell viability, migration and invasion and increased cell apoptosis in ovarian cancer cells.

Conclusion: The overexpression of lncRNA MEG3 inhibits cell proliferation and cell invasion and promotes apoptosis in ovarian cancer by sponging miR-205-5p.

Citing Articles

Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications.

Basu S, Nadhan R, Dhanasekaran D Cancers (Basel). 2025; 17(3).

PMID: 39941838 PMC: 11815776. DOI: 10.3390/cancers17030472.

Mechanisms of apoptosis-related non-coding RNAs in ovarian cancer: a narrative review.

Wang Y, Wang S, He H, Bai Y, Liu Z, Sabihi S Apoptosis. 2025; .

PMID: 39833637 DOI: 10.1007/s10495-024-02074-w.

A Comprehensive Bioinformatic Analysis Identifies a Tumor Suppressor Landscape of the MEG3 lncRNA in Breast Cancer.

Ahmadi A, Rezaei A, Khalaj-Kondori M, Khajehdehi M Indian J Surg Oncol. 2024; 15(4):752-761.

PMID: 39555361 PMC: 11564602. DOI: 10.1007/s13193-024-01992-0.

Genetic variants of LncRNAs HOTTIP and MEG3 influence nasopharyngeal carcinoma susceptibility and clinicopathologic characteristics in the Southern Chinese population.

Lao X, Wang Y, Huang R, He Y, Lu H, Liang D Infect Agent Cancer. 2024; 19(1):32.

PMID: 39049088 PMC: 11270775. DOI: 10.1186/s13027-024-00591-6.

Identification of long noncoding RNAs downregulated specifically in ovarian high-grade serous carcinoma.

Hayashi-Okada M, Sato S, Nakashima K, Sakai T, Tamehisa T, Kajimura T Reprod Med Biol. 2024; 23(1):e12572.

PMID: 38571514 PMC: 10988898. DOI: 10.1002/rmb2.12572.

References

Li Z, Yu X, Shen J . ANRIL: a pivotal tumor suppressor long non-coding RNA in human cancers. Tumour Biol. 2016; 37(5):5657-61. DOI: 10.1007/s13277-016-4808-5. View

Meseure D, Alsibai K, Nicolas A, Bieche I, Morillon A . Long Noncoding RNAs as New Architects in Cancer Epigenetics, Prognostic Biomarkers, and Potential Therapeutic Targets. Biomed Res Int. 2015; 2015:320214. PMC: 4584070. DOI: 10.1155/2015/320214. View

Chu P, Liang A, Jiang A, Zong L . miR-205 regulates the proliferation and invasion of ovarian cancer cells via suppressing PTEN/SMAD4 expression. Oncol Lett. 2018; 15(5):7571-7578. PMC: 5920363. DOI: 10.3892/ol.2018.8313. View

Zhao H, Wang X, Feng X, Li X, Pan L, Liu J . Long non-coding RNA MEG3 regulates proliferation, apoptosis, and autophagy and is associated with prognosis in glioma. J Neurooncol. 2018; 140(2):281-288. DOI: 10.1007/s11060-018-2874-9. View

Li L, Li S . miR-205-5p inhibits cell migration and invasion in prostatic carcinoma by targeting ZEB1. Oncol Lett. 2018; 16(2):1715-1721. PMC: 6036508. DOI: 10.3892/ol.2018.8862. View

Zhu F, Zheng F, Wang H, Zheng J, Zhang Q . Downregulation of lncRNA TUBA4B is Associated with Poor Prognosis for Epithelial Ovarian Cancer. Pathol Oncol Res. 2017; 24(2):419-425. DOI: 10.1007/s12253-017-0258-7. View

van Jaarsveld M, Helleman J, Berns E, Wiemer E . MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol. 2010; 42(8):1282-90. DOI: 10.1016/j.biocel.2010.01.014. View

Kinose Y, Sawada K, Nakamura K, Kimura T . The role of microRNAs in ovarian cancer. Biomed Res Int. 2014; 2014:249393. PMC: 4177088. DOI: 10.1155/2014/249393. View

Niu K, Shen W, Zhang Y, Zhao Y, Lu Y . MiR-205 promotes motility of ovarian cancer cells via targeting ZEB1. Gene. 2015; 574(2):330-6. DOI: 10.1016/j.gene.2015.08.017. View

10.

Wu M, Huang Y, Chen T, Wang W, Yang S, Ye Z . LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis. J Cell Mol Med. 2018; 23(1):29-38. PMC: 6307767. DOI: 10.1111/jcmm.13658. View

11.

Cai J, Fang L, Huang Y, Li R, Yuan J, Yang Y . miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res. 2013; 73(17):5402-15. DOI: 10.1158/0008-5472.CAN-13-0297. View

12.

Li J, Yang C, Li Y, Chen A, Li L, You Z . LncRNA GAS5 suppresses ovarian cancer by inducing inflammasome formation. Biosci Rep. 2017; 38(2). PMC: 5857912. DOI: 10.1042/BSR20171150. View

13.

Liu G, Zhao X, Zhou J, Cheng X, Ye Z, Ji Z . Long non-coding RNA MEG3 suppresses the development of bladder urothelial carcinoma by regulating miR-96 and TPM1. Cancer Biol Ther. 2018; 19(11):1039-1056. PMC: 6301801. DOI: 10.1080/15384047.2018.1480279. View

14.

Tripathi M, Doxtater K, Keramatnia F, Zacheaus C, Yallapu M, Jaggi M . Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes. Drug Discov Today. 2018; 23(9):1635-1643. PMC: 6139057. DOI: 10.1016/j.drudis.2018.04.010. View

15.

Chen Z, Tang Z, He Y, Liu L, Li D, Chen X . miRNA-205 is a candidate tumor suppressor that targets ZEB2 in renal cell carcinoma. Oncol Res Treat. 2014; 37(11):658-64. DOI: 10.1159/000368792. View

16.

Gulei D, Magdo L, Jurj A, Raduly L, Cojocneanu-Petric R, Moldovan A . The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression. Cell Death Dis. 2018; 9(2):66. PMC: 5833765. DOI: 10.1038/s41419-017-0102-8. View

17.

Jin L, Cai Q, Wang S, Wang S, Mondal T, Wang J . Long noncoding RNA MEG3 regulates LATS2 by promoting the ubiquitination of EZH2 and inhibits proliferation and invasion in gallbladder cancer. Cell Death Dis. 2018; 9(10):1017. PMC: 6170488. DOI: 10.1038/s41419-018-1064-1. View

18.

Ma Y, Lu Y, Lu B . MicroRNA and Long Non-Coding RNA in Ovarian Carcinoma: Translational Insights and Potential Clinical Applications. Cancer Invest. 2016; 34(9):465-476. DOI: 10.1080/07357907.2016.1227446. View

19.

Nagai H, Hasegawa S, Uchida F, Terabe T, Kanno N, Kato K . MicroRNA-205-5p suppresses the invasiveness of oral squamous cell carcinoma by inhibiting TIMP‑2 expression. Int J Oncol. 2018; 52(3):841-850. DOI: 10.3892/ijo.2018.4260. View

20.

Zhu M, Wang X, Gu Y, Wang F, Li L, Qiu X . MEG3 overexpression inhibits the tumorigenesis of breast cancer by downregulating miR-21 through the PI3K/Akt pathway. Arch Biochem Biophys. 2018; 661:22-30. DOI: 10.1016/j.abb.2018.10.021. View